NasdaqCM:RZLT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2028	51	-48	-42	-92	7
6/30/2027	3	-76	-62	-95	10
6/30/2026	N/A	-72	-68	-86	10
3/31/2026	N/A	-81	-73	-73	N/A
12/31/2025	N/A	-84	-77	-77	N/A
9/30/2025	N/A	-77	-70	-70	N/A
6/30/2025	N/A	-74	-69	-69	N/A
3/31/2025	N/A	-73	-66	-66	N/A
12/31/2024	N/A	-71	-63	-63	N/A
9/30/2024	N/A	-69	-63	-63	N/A
6/30/2024	N/A	-68	-57	-57	N/A
3/31/2024	N/A	-58	-50	-50	N/A
12/31/2023	N/A	-57	-53	-53	N/A
9/30/2023	N/A	-56	-48	-47	N/A
6/30/2023	N/A	-52	-45	-44	N/A
3/31/2023	N/A	-48	-45	-45	N/A
12/31/2022	N/A	-44	-41	-41	N/A
9/30/2022	N/A	-43	-41	-41	N/A
6/30/2022	N/A	-41	-40	-40	N/A
3/31/2022	N/A	-38	-33	-33	N/A
12/31/2021	N/A	-31	-24	-24	N/A
9/30/2021	N/A	-25	-23	-23	N/A
6/30/2021	N/A	-21	-20	-20	N/A
3/31/2021	N/A	-18	-19	-19	N/A
12/31/2020	N/A	-19	-20	-20	N/A
9/30/2020	N/A	-19	-19	-19	N/A
6/30/2020	N/A	-20	-24	-24	N/A
3/31/2020	N/A	-20	-24	-24	N/A
12/31/2019	N/A	-37	N/A	-27	N/A
9/30/2019	N/A	-34	N/A	-23	N/A
6/30/2019	N/A	-33	N/A	-15	N/A
3/31/2019	N/A	-42	N/A	-15	N/A
12/31/2018	N/A	-25	N/A	-9	N/A
9/30/2018	N/A	-27	N/A	-11	N/A
6/30/2018	N/A	-30	N/A	-14	N/A
3/31/2018	N/A	-24	N/A	-14	N/A
12/31/2017	N/A	-27	N/A	-15	N/A
9/30/2017	N/A	-27	N/A	-15	N/A
6/30/2017	N/A	-24	N/A	-13	N/A
3/31/2017	N/A	-27	N/A	-13	N/A
12/31/2016	N/A	-22	N/A	-12	N/A
9/30/2016	N/A	-21	N/A	-11	N/A
6/30/2016	N/A	-21	N/A	-10	N/A
3/31/2016	N/A	-14	N/A	-9	N/A
12/31/2015	N/A	-14	N/A	-9	N/A
9/30/2015	N/A	-12	N/A	-8	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RZLT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).

Earnings vs Market: RZLT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RZLT is expected to become profitable in the next 3 years.

Revenue vs Market: RZLT's revenue (75.5% per year) is forecast to grow faster than the US market (11.7% per year).

High Growth Revenue: RZLT's revenue (75.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RZLT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/15 15:58
End of Day Share Price	2026/05/15 00:00
Earnings	2026/03/31
Annual Earnings	2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rezolute, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Julian Harrison	BTIG
Edward Nash	Canaccord Genuity
Pete Stavropoulos	Cantor Fitzgerald & Co.

Rezolute Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Price target increased by 9.8% to US$5.63

Price target increased by 9.1% to US$4.50

Price target decreased by 74% to US$4.13

Forecast to breakeven in 2028

Price target increased by 7.1% to US$15.00

Price target increased by 12% to US$14.89

Recent updates

Price target increased by 9.8% to US$5.63

Rezolute Inc Announces Oral Presentation Of Results From Phase 3 Sunrize Study Of Ersodetug In Patients With Congenital Hyperinsulinism

Rezolute Inc Provides Update on Congenital Hyperinsulinism Program Following Fda Meeting

Will Rezolute (NASDAQ:RZLT) Spend Its Cash Wisely?

Price target increased by 9.1% to US$4.50

Rezolute, Inc. Provides Insights from Its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from Its Expanded Access Program in Tumor Hyperinsulinism

Chief Financial Officer recently bought US$80k worth of stock

Rezolute, Inc. Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Price target decreased by 74% to US$4.13

New major risk - Share price stability

Forecast to breakeven in 2028

New minor risk - Profitability

Price target increased by 7.1% to US$15.00

Price target increased by 12% to US$14.89

Here's Why We're Not Too Worried About Rezolute's (NASDAQ:RZLT) Cash Burn Situation

Rezolute, Inc., Annual General Meeting, Nov 19, 2025

No longer forecast to breakeven

Rezolute, Inc. Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism

Rezolute, Inc. Appoints Sunil Karnawat as Chief Commercial Officer, Effective August 18, 2025

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

Rezolute, Inc. announced that it has received $4.209995 million in funding

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute, Inc. has filed a Follow-on Equity Offering.

New minor risk - Share price stability

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $89.993096 million.

Rezolute, Inc. Announces Positive Recommendation After Independent Interim Analysis of Phase 3 Sunrize Study of Ersodetug in Congenital Hyperinsulinism

Chief Financial Officer recently bought US$58k worth of stock

Rezolute Appoints Erik Harris to Its Board of Directors

Rezolute: Late-Stage Study Targeting Hyperinsulinism

Rezolute, Inc. Provides Update on Its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Is Rezolute (NASDAQ:RZLT) In A Good Position To Deliver On Growth Plans?

New major risk - Shareholder dilution

Rezolute Receives Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Chief Financial Officer recently bought US$53k worth of stock

New minor risk - Share price stability

Price target increased by 7.5% to US$12.78

Rezolute, Inc., Annual General Meeting, Dec 05, 2024

Price target increased by 7.2% to US$12.75

Consensus EPS estimates upgraded to US$0.98 loss

Insufficient new directors

Price target increased by 8.1% to US$11.89

New major risk - Shareholder dilution

Rezolute, Inc. Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute, Inc. announced that it expects to receive $6 million in funding

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $59.99625 million.

New major risk - Share price stability

Price target increased by 9.4% to US$10.57

Rezolute, Inc. Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

Rezolute, Inc., Annual General Meeting, May 16, 2024

Director recently bought US$70k worth of stock

Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Chief Financial Officer recently bought US$67k worth of stock

Price target increased by 9.0% to US$8.50

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Now 29% overvalued after recent price rise

Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer

Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema

Rezolute Receives a Written Notice from the Listing Qualifications Department of Nasdaq Stock Market

New minor risk - Shareholder dilution

New minor risk - Share price stability

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation

New major risk - Revenue and earnings growth

Price target decreased by 30% to US$7.80

Rezolute, Inc. Provides an Update on Its Clinical Development Plans for RZ358